Binding Site Information of Target
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T51407 | Target Info | |||
| Target Name | Exportin-1 (XPO1) | ||||
| Synonyms | Exp1; Chromosome region maintenance 1 protein homolog; CRM1 | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | XPO1 | ||||
| Biochemical Class | Eukaryotic nuclear pore complex | ||||
| UniProt ID | |||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E,20R,21S)-17-ethyl-6,20-dihydroxy-3,5,7,9,11,15,21-heptamethyl-8-oxotetracosa-2,10,12,16,18-pentaenedioic acid | Ligand Info | |||||
| Structure Description | Human CRM1-RanGTP in complex with Leptomycin B | PDB:6TVO | ||||
| Method | X-ray diffraction | Resolution | 3.20 Å | Mutation | Yes | [1] |
| PDB Sequence |
LADHAARQLL
17 DFSQKLDINL27 LDNVVNCLYH37 GEGAQQRMAQ47 EVLTHLKEHP57 DAWTRVDTIL 67 EFSQNMNTKY77 YGLQILENVI87 KTRWKILPRN97 QCEGIKKYVV107 GLIIKTSSDP 117 TCVEKEKVYI127 GKLNMILVQI137 LKQEWPKHWP147 TFISDIVGAS157 RTSESLCQNN 167 MVILKLLSEE177 VFDFSSGQIT187 QVKSKHLKDS197 MCNEFSQIFQ207 LCQFVMENSQ 217 NAPLVHATLE227 TLLRFLNWIP237 LGYIFETKLI247 STLIYKFLNV257 PMFRNVSLKC 267 LTEIAGVSVS277 QYEEQFVTLF287 TLTMMQLKQM297 LPLNTNIRLA307 YSNGKDDEQN 317 FIQNLSLFLC327 TFLKEHDQLI337 EKRLNLRETL347 MEALHYMLLV357 SEVEETEIFK 367 ICLEYWNHLA377 AELYRESPFS387 TVPPRRQLYL410 PMLFKVRLLM420 VSRMAKPEEA 430 AAVENDQGEV440 VREFMKDTDS450 INLYKNMRET460 LVYLTHLDYV470 DTERIMTEKL 480 HNQVNGTEWS490 WKNLNTLCWA500 IGSISGAMHE510 EDEKRFLVTV520 IKDLLGLCEQ 530 KRGKDNKAII540 ASNIMYIVGQ550 YPRFLRAHWK560 FLKTVVNKLF570 EFMHETHDGV 580 QDMACDTFIK590 IAQKCRRHFV600 QVQVGEVMPF610 IDEILNNINT620 IICDLQPQQV 630 HTFYEAVGYM640 IGAQTDQTVQ650 EHLIEKYMLL660 PNQVWDSIIQ670 QATKNVDILK 680 DPETVKQLGS690 ILKTNVRACK700 AVGHPFVIQL710 GRIYLDMLNV720 YKCLSENISA 730 AIQANGEMVT740 KQPLIRSMRT750 VKRETLKLIS760 GWVSRSNDPQ770 MVAENFVPPL 780 LDAVLIDYQR790 NVPAAREPEV800 LSTMAIIVNK810 LGGHITAEIP820 QIFDAVFECT 830 LNMINKDFEE840 YPEHRTNFFL850 LLQAVNSHCF860 PAFLAIPPTQ870 FKLVLDSIIW 880 AFKHTMRNVA890 DTGLQILFTL900 LQNVAQEEAA910 AQSFYQTYFC920 DILQHIFSVV 930 TDTSHTAGLT940 MHASILAYMF950 NLVEEGKIST960 SLNPGNPVNN970 QIFLQEYVAN 980 LLKSAFPHLQ990 DAQVKLFVTG1000 LFSLNQDIPA1010 FKEHLRDFLV1020 QIKEFAGEDT 1030 S
|
|||||
|
|
LYS514
2.644
VAL518
4.271
ILE521
3.702
LYS522
3.684
LEU525
3.666
CYS528
1.768
GLU529
3.679
LYS537
2.685
ILE540
4.400
ALA541
3.433
ILE544
4.018
|
|||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Characterization of Inhibition Reveals Distinctive Properties for Human and Saccharomyces cerevisiae CRM1. J Med Chem. 2020 Jul 23;63(14):7545-7558. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.